Global is Going Mobile; Global WholeHealth Partners Corp (GWHP-OTC) has Signed an Agreement With Dr. Vu Le to be the Medical Director for the CLIA WAIVED Mobile Laboratory
Global WholeHealth Partners Corp (GWHP: OTC) is enhancing COVID-19 testing by providing services directly to schools and workplaces. The company utilizes a CLIA WAIVED lab to conduct tests for COVID-19 Antigen and Antibody, along with other diagnostic tests. With an expansive lineup of 56 FDA-approved products, including 15 POC tests, Global is committed to offering rapid testing solutions. The company emphasizes the importance of swift results to help curb the spread of the virus, leveraging advanced IVD technology for detecting SARS-CoV-2 antibodies.
- Utilizes a CLIA WAIVED lab for COVID-19 testing at schools and workplaces.
- Offers 56 FDA-approved products and 15 CLIA WAIVED POC tests.
- Emphasizes rapid testing, enhancing response to COVID-19 spread.
- None.
Global WholeHealth Partners Corp (GWHP: OTC) is bringing the testing to you, to your school or to your work. 8k filed on 05/14/2021.
Global will be using this CLIA WAIVED Lab to test for COVID 19 Antigen, Antibody, and the other 15 tests that are CLIA WAIVED that Global carries.
San Clemente, CA, May 20, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Global WholeHealth Partners Corp. (OTC: GWHP) offers one of the largest lines of COVID 19 tests. Global WholeHealth Partners Corp (OTC: GWHP) states that the Antibody IgG/IgM tests that they offer are capable of detecting all the current identified SARS-CoV-2 viruses. The strains identified in the United Kingdom (B.1.1.7), South Africa (B.1.351), and Brazil (P.1) strain contains multiple mutations, most reflected in the S gene, which encodes the spike protein. Global understands the need to be ahead of the virus to conquer the virus.
Global WholeHealth Partners recognizes that there is a crucial need for faster testing and faster results when it comes to fighting the COVID. Global WholeHealth Partners knows that the quicker the test results can be reviewed by a Front-Line Healthcare Worker, the quicker we can stop the spread of this disease.
Global WholeHealth Partners Corp. provides cutting edge technology using In-vitro Diagnostic (IVD) Real-Time PCR Machines for detection of SARS-CoV-2 IgM/IgG antibodies in human serum, plasma, or whole blood. It has led the fight against vector borne terminal diseases such as Ebola, ZIKA, Dengue, Malaria, Influenza and Tuberculosis, Corona Viruses, and among other vector borne diseases, with an FDA Certificate of Exportability (2260-11-2019). The company was founded on March 7, 2013 and is headquartered in San Clemente, CA.
GWHP develops, manufactures, and markets in vitro diagnostic (IVD) tests for OTC, or consumer-use as well as professional rapid diagnostic point-of-care (POC) test kits for hospitals, physicians’ offices, and medical clinics in the US and abroad. Notably, The Company offers 56 products FDA approved and many are Approved for OTC use, and 15 POC products approved by the CLIA WAIVED FDA.
Media Contact:
Name: Charles Strongo,
CEO, Global WholeHealth Partners Corp.
Email: Sales@gwhpcorp.com
Forward-Looking Statements
This press release contains "forward-looking statements.” Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) market acceptance of our existing and new products, (ii) negative clinical trial results or lengthy product delays in key markets, (iii) an inability to secure regulatory approvals for the sale of our products, (iv) intense competition in the medical device industry from much larger, multinational companies, (v) product liability claims, (vi) product malfunctions, (vii) our limited manufacturing capabilities and reliance on subcontractors for assistance, (viii) insufficient or inadequate reimbursement by governmental and other third party payers for our products, (ix) our efforts to successfully obtain and maintain intellectual property protection covering our products, which may not be successful, (x) legislative or regulatory reform of the healthcare system in both the U.S. and foreign jurisdictions, (xi) our reliance on single suppliers for certain product components, (xii) the fact that we will need to raise additional capital to meet our business requirements in the future and that such capital raising may be costly, dilutive or difficult to obtain and (xiii) the fact that we conduct business in multiple foreign jurisdictions, exposing us to foreign currency exchange rate fluctuations, logistical and communications challenges, burdens and costs of compliance with foreign laws and political and economic instability in each jurisdiction. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC's web site at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.
FAQ
What types of tests does Global WholeHealth Partners Corp (GWHP) offer?
How does GWHP support COVID-19 testing efforts?
What is the significance of the FDA approval for GWHP's products?
How many FDA-approved products does GWHP have?
What is the focus of GWHP's diagnostics technology?
